

Novel Sensor Monitors Endograft Leaks Remotely

BY TIMOTHY F. KIRN
Sacramento Bureau

SCOTTSDALE, ARIZ. — Vascular interventionalists may soon routinely implant pressure sensors that can detect endoleaks during both thoracic and abdominal aneurysm repair.

“Remote pressure sensing for endovascular repair is feasible,” Dr. Ross Milner said at an international symposium on endovascular interventions sponsored by the Arizona Heart Foundation. The sensors have no battery. They are activated by energy waves generated by external probes, which also read the measurement.

In a recent publication, Dr. Milner, of the division of vascular surgery at Emory University, Atlanta, said there are two devices in development, one that uses ultrasound waves and the other, radio waves.

Fibrin Glue Seals Endoleaks After Aneurysm Repair

SCOTTSDALE, ARIZ. — Type II endoleaks after endovascular aneurysm repair were prevented by using fibrin glue in all but 2 of 84 consecutive patients, Dr. Mauro Zanchetta said at an international congress on endovascular interventions sponsored by the Arizona Heart Foundation.

The patients were treated over a 2-year period, up to December 2005, with a mean follow-up period of 14 months, at which time 76 of the patients had no complications, he said. The complications that did occur were not due to the fibrin glue, which induces thrombosis of the side branch vessels. There were graft-deployment problems in two patients, implantation problems in two patients, and systemic complications in three patients. One patient died during the procedure.

In all patients without endoleak, subsequent examinations showed sustained aneurysm shrinkage. The fibrin glue treatment is “easy, effective, and durable,” said Dr. Zanchetta of the Ospedale di Cittadella in Padua, Italy. “This approach reveals a new strategy for routine prevention of type II endoleaks.” He said the bifurcated grafts were deployed from a right femoral access. The fibrin sealant (5 mL) was injected directly into the aneurysm sac using a double-syringe delivery system inserted through a 23-cm, 5-F sheath, and advanced from a left access over a guidewire that remained in place after angiography between the aorta and the graft. A balloon was inflated in the left limb of the stent graft to prevent the sealant from leaking and causing distal embolization. It was left in place for 1 minute after injection. Intraoperative angiography and color Doppler ultrasound showed the majority of the patent side branches found and treated were peripheral lumbar arteries, with a range of one to three per patient. Ten patients also had patent inferior mesenteric arteries treated.

—Timothy F. Kirn

Both devices—the ImPressure ultrasound device, Remon Medical Technologies Inc., and the Endosensor, CardioMEMS Inc.—have been implanted in human trials.

The Endosensor device was approved for U.S. marketing in November, based on a 12-center trial. In a report on the trial at the most recent Society for Vascular Surgery meeting, the investigators said the device was implanted in 70 patients undergoing endovascular repair of abdominal aortic aneurysms without complication. It

accurately measured pressure in 65 of the patients and detected all 15 endoleaks that occurred during the procedure.

Dr. Milner and his colleagues at Emory have begun using the ImPressure device in thoracic aneurysm repairs, with the first implant done in Brazil last July. That device continued to function well 8 months after implantation, and it has shown a dramatic, continued drop in pulse pressure within the aneurysm sac.

He predicted that, in time, use of these

pressure devices may omit the need for CT angiography at the end of procedures to be sure the graft has completely sealed off the aneurysm, thus sparing patients some exposure to contrast agent. “Pressure sensing will be feasible in the thoracic aorta and may add a lot to the follow-up of these patients as it allows for appropriate intraoperative exclusion as well as long-term follow-up,” he said. The sensors are compatible with any graft system, he added. ■

REST ASSURED: the facts are on your side when ordering NATRECOR®

Fact 1: NATRECOR® (nesiritide) is the only approved acute heart failure therapy clinically proven to safely and effectively improve filling pressures and patient-reported dyspnea (in patients with dyspnea at rest or with minimal activity).^{1,2}

Fact 2: No other treatment for Acutely Decompensated Congestive Heart Failure (ADHF) has been proven in large controlled studies to provide rapid relief of dyspnea.² Clinical evaluations of diuretics, nitroglycerin, and nitroprusside in patients with ADHF are virtually nonexistent.³

Fact 3: Since approval in 2001, hundreds of thousands of hospitalized patients suffering with ADHF have experienced symptom relief with NATRECOR® for their breathing difficulties.⁴

Fact 4: More information from controlled clinical trials exists about NATRECOR® than for any other therapy currently available to treat ADHF.²

Fact 5: None of the seven clinical trials conducted with nesiritide were designed with an intention of evaluating mortality. The low number of deaths and the variability in the treatment groups make it difficult to draw meaningful conclusions about mortality.

Fact 6: The single largest randomized controlled trial of an approved inotropic agent in ADHF showed no benefit and an increased risk of adverse events.⁵ The use of high-dose diuretics and inotropes has been associated with worsened outcomes in patients with ADHF.⁶⁻⁹

At Scios, we are committed to providing physicians and their patients with breakthrough treatments in heart failure. Our ongoing clinical trial program represents the largest ADHF research effort in the industry.

Please visit www.natreacor.com to learn more about NATRECOR® and how your acute heart failure patients may benefit.

Intravenous
B-type natriuretic peptide (BNP)
NATRECOR®
(nesiritide)